Amitkumar Mehta, MD, MBA

An expert discusses the rapidly evolving landscape of ITP treatments, highlighting emerging therapies such as Bruton’s tyrosine kinase inhibitors, neonatal Fc receptor antagonists, anti-CD38 antibodies, and innovative approaches like CAR T-cell therapy that offer new hope for improved patient outcomes.

An expert discusses the expanded treatment options for refractory ITP, emphasizing accurate diagnosis, combination therapies targeting platelet production and destruction, and the evolving role of splenectomy with improved safety measures.

An expert discusses how ITP treatment success is monitored through maintaining safe platelet levels and symptom control, managing relapses, and tailoring follow-up based on therapy type and patient needs.

An expert discusses the importance of balancing efficacy with safety in ITP treatment, emphasizing cautious use of steroids, close monitoring of therapy-related side effects, and maintaining platelet counts just above bleeding thresholds to minimize long-term drug toxicity through personalized, informed care.

An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic immune thrombocytopenic purpura (ITP), highlighting proactive strategies like emergency steroids, shared decision-making, and interdisciplinary care to align therapy choices with each patient’s lifestyle, preferences, and comorbidities.

An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions based on platelet count, bleeding symptoms, and comorbidities, with options ranging from observation to urgent therapies like steroids or IVIG, and longer-term approaches tailored to patient health, treatment goals, and lifestyle considerations.

An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions based on platelet count, bleeding symptoms, and comorbidities, with options ranging from observation to urgent therapies like steroids or IVIG, and longer-term approaches tailored to patient health, treatment goals, and lifestyle considerations.

An expert discusses the clinical presentation and diagnosis of immune thrombocytopenic purpura (ITP), emphasizing that isolated thrombocytopenia with mucosal bleeding and petechiae is highly suggestive of ITP, while underscoring the importance of ruling out other causes—especially drug-induced thrombocytopenia—through careful evaluation.